Trial Profile

Phase 2a randomized, placebo-controlled, double-blind trial will evaluate three months of 250 mg daily CIR-0602K

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azemiglitazone (Primary)
Indications Type 1 diabetes mellitus
Focus Therapeutic Use

Most Recent Events

04 Nov 2025 Planned number of patients changed to 34.
04 Nov 2025 New trial record
17 Sep 2025 According to the Cirius Therapeutics Media Release, A Phase 2a study in people with type 1 diabetes (T1D) and supported in part by Breakthrough T1D is expected to open and begin enrollment in 4Q25.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com